Emanuele Vita
A5037537100- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer therapeutics and mechanisms
- Amyloidosis: Diagnosis, Treatment, Outcomes
- AI in cancer detection
- Metastasis and carcinoma case studies
- Inflammatory Biomarkers in Disease Prognosis
- RNA modifications and cancer
- Neuroendocrine Tumor Research Advances
- Intraperitoneal and Appendiceal Malignancies
- Peptidase Inhibition and Analysis
- Neuroblastoma Research and Treatments
- Colorectal and Anal Carcinomas
- Gastrointestinal Tumor Research and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Pleural and Pulmonary Diseases
- SARS-CoV-2 and COVID-19 Research
- Cancer Diagnosis and Treatment
Agostino Gemelli University Polyclinic
2019-2025
Università Cattolica del Sacro Cuore
2018-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2025
University of California, San Francisco
1994
Background: As COVID-19 has become an epidemic, we conducted open-label study aimed to identify immunogenicity and reactogenicity of boosters the BNT162b2 vaccine in a real-world cohort long-survivor metastatic lung cancer patients (LS-mLC pts). Methods Analysis: According timing booster dose (BD) SARS-CoV-2 infection (Cov-I) during anticancer treatment (ACT), between October 2021 February 2022, prospectively enrolled 166 into five parallel cohorts. The primary endpoints were seroprevalence...
Abstract Precision oncology has transformed non-small cell lung cancer (NSCLC) treatment by tailoring therapies to the genomic profile of disease, significantly improving clinical outcomes. However, acquired resistance molecularly targeted remains a major challenge. This report details 69-year-old woman with KRAS G12C-mutant metastatic NSCLC who developed sotorasib, G12C inhibitor. Initially responding standard dose 960 mg, patient required reduction 480 mg due liver toxicity. After 20...
The current management of lung cancer patients has reached a high level complexity. Indeed, besides the traditional clinical variables (e.g., age, sex, TNM stage), new omics data have recently been introduced in practice, thereby making more complex decision-making process. With advent Artificial intelligence (AI) techniques, various datasets may be used to create accurate predictive models paving way for better care patients.The LANTERN study is multi-center observational trial involving...
Abstract Background While immune checkpoint inhibitors (ICIs) are increasingly reshaping the therapeutic landscape of non‐small‐cell lung cancer (NSCLC), only a limited proportion patients achieve relevant and long‐lasting benefit with these treatments, calling for identification clinical and, ideally modifiable, predictors efficacy. Body composition phenotypes may reflect aspects patients' immunology thereby their ability to respond ICIs. This study aims explore possible association between...
Background: Pembrolizumab is approved in monotherapy for the first-line (1L) of advanced or metastatic NSCLC patients with high PD-L1 (≥50%). Despite a proportion achieve long-term survival, about one-third experience detrimental survival outcomes, including early death, hyperprogression, and fast progression. The impact clinical factors on progression (EP) development has not been widely explored. Methods: We designed retrospective, multicenter study involving five Italian centers, ≥ 50%,...
Abstract Background Only few ES-SCLC patients experience long-term survival benefit by maintenance IT. Adipokines-induced metabolic meta-inflammation has been related to enhanced responsiveness IT in obese patients; however, their prognostic role SCLC is currently controversial. Methods Pre-treatment CT scan was used for determining distribution of abdominal adiposity, and blood samples were collected at fasting measuring glycemia, insulin, ghrelin, leptin adipokines (TNF-α, IFN-γ, IL-6...
Abstract Background Identifying the patients who may benefit most from immune checkpoints inhibitors remains a great challenge for clinicians. Here we investigate on blood serum amyloid A (SAA) as biomarker of response to upfront pembrolizumab in with advanced non-small-cell lung cancer (NSCLC). Methods Patients PD-L1 ≥ 50% receiving (P cohort) and 0–49% treated chemotherapy (CT were evaluated SAA radiological at baseline every 9 weeks. Endpoints rate (RR) according RECIST1.1,...